Item 5. Other Information
3K characters. Original on sec.gov ·
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
During the quarter ended March 31, 2025, the following officers, as defined in Rule 16a-1(f), and director adopted or terminated a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, that are each intended to satisfy the affirmative defense in Rule 10b5-1(c), as follows:
| Name and Title | Action | Date of Adoption or Termination | Expiration Date | Maximum Aggregate Number of Class A Shares to be Sold | ||||||||||||||||||||||
| Amrita Ahuja Chief Operating Officer & Chief Financial Officer | Adoption | February 25, 2025 | May 27, 2026, or earlier if all transactions are completed | 178,963 | ||||||||||||||||||||||
| Chrysty Esperanza Chief Legal Officer | Adoption | February 25, 2025 | June 2, 2026, or earlier if all transactions are completed | 3,000 | ||||||||||||||||||||||
| Dhananjay Prasanna Technology + Engineering Lead | Adoption | February 25, 2025 | May 27, 2026, or earlier if all transactions are completed | 111,734 | ||||||||||||||||||||||
| Anthony Eisen Director | Adoption | February 25, 2025 | May 27, 2026, or earlier if all transactions are completed | 310,000 | ||||||||||||||||||||||
| Brian Grassadonia Ecosystem Lead | Adoption | March 3, 2025 (i) | June 2, 2026, or earlier if all transactions are completed | 56,905 | ||||||||||||||||||||||
| Brian Grassadonia Ecosystem Lead | Termination (ii) | March 19, 2025 | March 30, 2025, or earlier if all transactions are completed | 652,282 |
(i) On March 26, 2025, Mr. Grassadonia terminated this Rule 10b5-1 trading arrangement prior to the execution of any trades.
(ii) Trading arrangement was originally adopted on November 29, 2023.
No other officers, as defined in Rule 16a-1(f), or directors adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the last fiscal quarter.
Previous: Item 1A. Risk Factors · Next: Item 6. Exhibits